Mechanisms of hepatocellular carcinoma and challenges and opportunities for molecular targeted therapy

World Journal of Hepatology

Volumn 7, Issue 15, 2015, Pages 1964-1970

  Chen, Chuan ^a   Wang, Ge ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Cancer stem cell; Hepatocellular carcinoma; Molecular targeted therapy; Oncogene; Signal pathway

Indexed keywords

EID: 84938224557     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v7.i15.1964     Document Type: Short Survey

References (45)

1. Matsuda T, Saika K. Trends in liver cancer mortality rates in Japan, USA, UK, France and Korea based on the WHO mortality database. Jpn J Clin Oncol 2012; 42: 360-361 [PMID: 22457364 DOI: 10.1093/jjco/hys048]
2. Sintra SN, Tomé L, Cipriano MA, Bento C, Furtado E. Longterm outcome of the first 150 liver transplant recipients: a singlecenter experience. Transplant Proc 2013; 45: 1119-1121 [PMID:23622641 DOI: 10.1016/j.transproceed.2013.02.101]
3. Zhao M, He HW, Sun HX, Ren KH, Shao RG. Dual knockdown of N-ras and epiregulin synergistically suppressed the growth of human hepatoma cells. Biochem Biophys Res Commun 2009; 387:239-244 [PMID: 19563783 DOI: 10.1016/j.bbrc.2009.06.128]
4. Zhang X, Ding HG. Key role of hepatitis B virus mutation in chronic hepatitis B development to hepatocellular carcinoma. World J Hepatol 2015; 7: 1282-1286 [PMID: 26019744 DOI:10.4254/wjh.v7.i9.1282]
5. Jeon YE, Lee SC, Paik SS, Lee KG, Jin SY, Kim HR, Yoo CW, Park HM, Han SY, Choi DH, Kim HK. Histology-directed matrixassisted laser desorption/ionization analysis reveals tissue origin and p53 status of primary liver cancers. Pathol Int 2011; 61: 449-455 [PMID: 21790858 DOI: 10.1111/j.1440-1827.2011.02686.x]
6. Boiko AD, Porteous S, Razorenova OV, Krivokrysenko VI, Williams BR, Gudkov AV. A systematic search for downstream mediators of tumor suppressor function of p53 reveals a major role of BTG2 in suppression of Ras-induced transformation. Genes Dev 2006; 20: 236-252 [PMID: 16418486]
7. Zhang Z, Chen C, Wang G, Yang Z, San J, Zheng J, Li Q, Luo X, Hu Q, Li Z, Wang D. Aberrant expression of the p53-inducible antiproliferative gene BTG2 in hepatocellular carcinoma is associated with overexpression of the cell cycle-related proteins. Cell Biochem Biophys 2011; 61: 83-91 [PMID: 21327578 DOI:10.1007/s12013-011-9164-x]
8. Galuppo R, Ramaiah D, Ponte OM, Gedaly R. Molecular therapies in hepatocellular carcinoma: what can we target? Dig Dis Sci 2014; 59: 1688-1697 [PMID: 24573715 DOI: 10.1007/s10620-014-3058-x]
9. Galuppo R, Maynard E, Shah M, Daily MF, Chen C, Spear BT, Gedaly R. Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-catenin pathways. Anticancer Res 2014; 34: 1709-1713 [PMID: 24692700]
10. Zhou Q, Lui VW, Yeo W. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma. Future Oncol 2011; 7: 1149-1167 [PMID: 21992728 DOI: 10.2217/fon.11.95]
11. Grabinski N, Ewald F, Hofmann BT, Staufer K, Schumacher U, Nashan B, Jücker M. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer 2012; 11: 85 [PMID: 23167739 DOI:10.1186/1476-4598-11-85]
12. Thompson MD, Monga SP. WNT/beta-catenin signaling in liver health and disease. Hepatology 2007; 45: 1298-1305 [PMID:17464972]
13. Langeswaran K, Gowthamkumar S, Vijayaprakash S, Revathy R, Balasubramanian MP. Influence of limonin on Wnt signalling molecule in HepG2 cell lines. J Nat Sci Biol Med 2013; 4: 126-133 [PMID: 23633848 DOI: 10.4103/0976-9668.107276]
14. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022 [PMID: 21374666 DOI:10.1002/hep.24199]
15. Calvisi DF, Factor VM, Loi R, Thorgeirsson SS. Activation of beta-catenin during hepatocarcinogenesis in transgenic mouse models: relationship to phenotype and tumor grade. Cancer Res 2001; 61: 2085-2091 [PMID: 11280770]
16. Cha MY, Kim CM, Park YM, Ryu WS. Hepatitis B virus X protein is essential for the activation of Wnt/beta-catenin signaling in hepatoma cells. Hepatology 2004; 39: 1683-1693 [PMID:15185310]
17. Srisuttee R, Koh SS, Kim SJ, Malilas W, Boonying W, Cho IR, Jhun BH, Ito M, Horio Y, Seto E, Oh S, Chung YH. Hepatitis B virus X (HBX) protein upregulates β-catenin in a human hepatic cell line by sequestering SIRT1 deacetylase. Oncol Rep 2012; 28:276-282 [PMID: 22562294 DOI: 10.3892/or.2012.1798]
18. Wang Y, Han C, Lu L, Magliato S, Wu T. Hedgehog signaling pathway regulates autophagy in human hepatocellular carcinoma cells. Hepatology 2013; 58: 995-1010 [PMID: 23504944 DOI:10.1002/hep.26394]
19. Berman DM, Karhadkar SS, Maitra A, Montes De Oca R, Gerstenblith MR, Briggs K, Parker AR, Shimada Y, Eshleman JR, Watkins DN, Beachy PA. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours. Nature 2003; 425: 846-851 [PMID: 14520411]
20. Arzumanyan A, Sambandam V, Clayton MM, Choi SS, Xie G, Diehl AM, Yu DY, Feitelson MA. Hedgehog signaling blockade delays hepatocarcinogenesis induced by hepatitis B virus X protein. Cancer Res 2012; 72: 5912-5920 [PMID: 22986746 DOI:10.1158/0008-5472]
21. Sicklick JK, Li YX, Jayaraman A, Kannangai R, Qi Y, Vivekanandan P, Ludlow JW, Owzar K, Chen W, Torbenson MS, Diehl AM. Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis. Carcinogenesis 2006; 27: 748-757 [PMID:16339184]
22. Kim Y, Yoon JW, Xiao X, Dean NM, Monia BP, Marcusson EG. Selective down-regulation of glioma-associated oncogene 2 inhibits the proliferation of hepatocellular carcinoma cells. Cancer Res 2007; 67: 3583-3593 [PMID: 17440069]
23. Strazzabosco M, Fabris L. Notch signaling in hepatocellular carcinoma: guilty in association! Gastroenterology 2012; 143:1430-1434 [PMID: 23099244 DOI: 10.1053/j.gastro.2012.10.025]
24. Villanueva A, Alsinet C, Yanger K, Hoshida Y, Zong Y, Toffanin S, Rodriguez-Carunchio L, Solé M, Thung S, Stanger BZ, Llovet JM. Notch signaling is activated in human hepatocellular carcinoma and induces tumor formation in mice. Gastroenterology 2012; 143: 1660-1669.e7 [PMID: 22974708 DOI: 10.1053/j. gastro.2012.09.002]
25. Viatour P, Ehmer U, Saddic LA, Dorrell C, Andersen JB, Lin C, Zmoos AF, Mazur PK, Schaffer BE, Ostermeier A, Vogel H, Sylvester KG, Thorgeirsson SS, Grompe M, Sage J. Notch signaling inhibits hepatocellular carcinoma following inactivation of the RB pathway. J Exp Med 2011; 208: 1963-1976 [PMID:21875955 DOI: 10.1084/jem.20110198]
26. Enguita-Germán M, Fortes P. Targeting the insulin-like growth factor pathway in hepatocellular carcinoma. World J Hepatol 2014; 6: 716-737 [PMID: 25349643 DOI: 10.4254/wjh.v6.i10.716]
27. Sprinzl MF, Puschnik A, Schlitter AM, Schad A, Ackermann K, Esposito I, Lang H, Galle PR, Weinmann A, Heikenwälder M, Protzer U. Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion. J Hepatol 2015; 62: 863-870 [PMID: 25463538 DOI:10.1016/j.jhep.2014.11.011]
28. Goyal L, Muzumdar MD, Zhu AX. Targeting the HGF/c-MET pathway in hepatocellular carcinoma. Clin Cancer Res 2013; 19: 2310-2318 [PMID: 23388504 DOI: 10.1158/1078-0432. CCR-12-2791]
29. You H, Ding W, Dang H, Jiang Y, Rountree CB. c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology 2011; 54: 879-889 [PMID:21618573 DOI: 10.1002/hep.24450]
30. Berasain C, Avila MA. The EGFR signalling system in the liver:from hepatoprotection to hepatocarcinogenesis. J Gastroenterol 2014; 49: 9-23 [PMID: 24318021 DOI: 10.1007/s00535-013-0907-x]
31. Chan LH, Luk ST, Ma S. Turning hepatic cancer stem cells inside out--a deeper understanding through multiple perspectives. Mol Cells 2015; 38: 202-209 [PMID: 25666349 DOI: 10.14348/ molcells.2015.2356]
32. Sukowati CH, Tiribelli C. The biological implication of cancer stem cells in hepatocellular carcinoma: a possible target for future therapy. Expert Rev Gastroenterol Hepatol 2013; 7: 749-757 [PMID: 24161136 DOI: 10.1586/17474124.2013.846826]
33. Baumann U, Crosby HA, Ramani P, Kelly DA, Strain AJ. Expression of the stem cell factor receptor c-kit in normal and diseased pediatric liver: identification of a human hepatic progenitor cell? Hepatology 1999; 30: 112-117 [PMID: 10385646]
34. Song K, Wu J, Jiang C. Dysregulation of signaling pathways and putative biomarkers in liver cancer stem cells (Review). Oncol Rep 2013; 29: 3-12 [PMID: 23076400 DOI: 10.3892/or.2012.2082]
35. Rountree CB, Mishra L, Willenbring H. Stem cells in liver diseases and cancer: recent advances on the path to new therapies. Hepatology 2012; 55: 298-306 [PMID: 22030746 DOI: 10.1002/ hep.24762]
36. Takeda H, Nishikawa H, Iguchi E, Ohara Y, Sakamoto A, Saito S, Nishijima N, Nasu A, Komekado H, Kita R, Kimura T, Osaki Y. Effect of treatment with branched-chain amino acids during sorafenib therapy for unresectable hepatocellular carcinoma. Hepatol Res 2014; 44: 302-312 [PMID: 23607614 DOI: 10.1111/hepr.12125]
37. Piscaglia F, Salvatore V, Venerandi L. Field practice studies on sorafenib: lessons in systemic treatment of hepatocellular carcinoma. Dig Liver Dis 2013; 45: 367-368 [PMID: 23562444 DOI: 10.1016/j.dld.2013.02.018]
38. Coriat R, Nicco C, Chéreau C, Mir O, Alexandre J, Ropert S, Weill B, Chaussade S, Goldwasser F, Batteux F. Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. Mol Cancer Ther 2012; 11: 2284-2293 [PMID: 22902857 DOI: 10.1158/1535-7163. MCT-12-0093]
39. Zhang HL, Zhu Y, Qin XJ, Wang CF, Yao XD, Zhang SL, Dai B, Zhu YP, Shi GH, Ye DW. c-KIT: potential predictive factor for the efficacy of sorafenib in metastatic renal cell carcinoma with sarcomatoid feature. Clin Genitourin Cancer 2013; 11: 134-140 [PMID: 23058498 DOI: 10.1016/j.clgc.2012.08.007]
40. Yamasaki T, Terai S, Sakaida I. Deferoxamine for advanced hepatocellular carcinoma. N Engl J Med 2011; 365: 576-578 [PMID: 21830988 DOI: 10.1056/NEJMc1105726]
41. Rimassa L, Pressiani T, Boni C, Carnaghi C, Rota Caremoli E, Fagiuoli S, Foa P, Salvagni S, Cortesi E, Chiara Tronconi M, Personeni N, Bozzarelli S, Chiara Banzi M, Fanello S, Romano Lutman F, Giordano L, Santoro A. A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma. Oncologist 2013; 18: 379-380 [PMID: 23580239 DOI:10.1634/theoncologist]
42. Shen YC, Hsu C, Cheng AL. Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. J Gastroenterol 2010; 45: 794-807 [PMID: 20567987 DOI: 10.1007/s00535-010-0270-0]
43. Tian T, Nan KJ, Wang SH, Liang X, Lu CX, Guo H, Wang WJ, Ruan ZP. PTEN regulates angiogenesis and VEGF expression through phosphatase-dependent and -independent mechanisms in HepG2 cells. Carcinogenesis 2010; 31: 1211-1219PMID:20430845 DOI: 10.1093/carcin/bgq085]
44. Park JW, Finn RS, Kim JS, Karwal M, Li RK, Ismail F, Thomas M, Harris R, Baudelet C, Walters I, Raoul JL. Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2011; 17: 1973-1983 [PMID: 21349999 DOI: 10.1158/1078-0432.CCR-10-2011]
45. Finn RS, Kang YK, Mulcahy M, Polite BN, Lim HY, Walters I, Baudelet C, Manekas D, Park JW. Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma. Clin Cancer Res 2012; 18: 2090-2098 [PMID: 22238246 DOI: 10.1158/1078-0432.CCR-11-1991]